Delivery Systems, Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Conditions
Brief summary
This study is conducted in Asia. The aim of this observational study is to evaluate subjects' treatment satisfaction and to evaluate subjects' preference of pen device and the incidence of clinical technical complains while using NovoPen® 4 under normal clinical practice conditions.
Interventions
DEVICENovoPen® 4
Insulin administration by means of a NovoPen® 4 pen device
Sponsors
Novo Nordisk A/S
Study design
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Any subject with Type 1 or Type 2 diabetes and accepting to use NovoPen® 4. The selection will be at the discretion of the individual physician. * A study specific signed informed consent must be signed by each subject before any study-related activities or information is collected, if required by local regulations
Exclusion criteria
* Subjects who are unlikely to comply with the protocol, e.g., unwillingness to cooperate, inability to return for the final visit * Subjects with known or suspected allergy to any insulin or any of its excipients
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The change in subjects' satisfaction with insulin therapy, measured by change from visit 1 to visit 2 in subject treatment satisfaction scores on the DTSQ (Diabetes Treatment Satisfaction Questionnaire) | 3 months |
Secondary
| Measure | Time frame |
|---|---|
| Subjects' device preference | 3 months |
| Subjects' NovoPen® 4 evaluation | 3 months |
| Number of clinical technical complaints | 3 months |
Countries
China
Outcome results
None listed